African swine fever (ASF) virus is a double-stranded DNA virus (6, 9) . Viral DNA synthesis takes place in the cell nucleus (19) , whereas assembly occurs in the cytoplasm. Based on its icosahedral morphology it has been classified among the Iridoviridae family of viruses (12) , and like the other members of this virus family which infect vertebrates, it has an external envelop which is acquired when it buds through the plasma membrane (2) . The enzymatic composition of ASF virus seems rather complex, because virus particles contain a DNA-dependent RNA polymerase similar to that present in poxvirus virion particles (10) . In addition, nucleoside triphosphate phosphohydrolase (11) and protein kinase (17) activities have been reported. A specific viral DNA polymerase and DNA topoisomerase are also induced in virus-infected cells (16, 18) . Based on this array of virus-encoded enzymes and on the existence of cross-links in the genome of the ASF virus (15) , it has been suggested that in the early phase of gene expression the virus uses a molecular strategy for replication similar to that of poxviruses (10, 15) .
Because of the peculiarities of the virus, no neutralizing antibodies can be detected in infected animals. For this reason, prospects are poor for developing a vaccine by conventional methods; therefore, attention has been concentrated on those chemical agents that are capable of inhibiting viral replication. Relatively preliminary studies have shown that phosphonoacetic acid (8, 14) , 5-iodo-2'-deoxyuridine (8, 9) , and rifampin (3) and chloroquine (7) may inhibit viral replication in vitro.
Previous results from our laboratory indicate that compounds such as actinobolin, tetracenomycin C, megalomycin C, suramin, atropine, and carrageenan show activity against herpesvirus replication (1). These agents were evaluated for their capacity to inhibit ASF virus replication. Estimation of the cytopathic effect. Monolayers of Vero cells grown in 24-well plates were infected with ASF virus at a multiplicity of 0.5 PFU per cell in the presence of different concentrations of each compound. After 48 h of incubation, the cell monolayer was examined under a phase-contrast microscope, and the cytopathic effect in infected cells and the cytotoxic effect in uninfected cells were recorded. In addition, protein synthesis was estimated as described previously (1). Briefly, the culture medium was removed and 1 ,Ci of [35S]methionine (800 Ci/mmol; Radiochemical Centre, Amersham, England) per ml was added in Dulbecco modified Eagle medium without methionine and incubated for 1 h at 37°C. Afterwards, the radioactive medium was removed, and the cell monolayer was precipitated with 1 ml of 5% trichloroacetic acid. Nonprecipitable material was removed, and the cell monolayer was washed twice with ethanol and dried and dissolved with 250 ,ul of 0.1 N NaOH-1% sodium dodecyl sulfate. A total of 125 RI was counted in a liquid scintillation spectrometer (Intertechnique).
MATERIALS AND METHODS

Measurement of production of ASF virus infectious units.
For infection and plaque titration, cell monolayers were grown in 24-well plates. After cell growth, the medium was discarded and ASF virus was added at a multiplicity of infection of 0.5. After a 1.5-h adsorption period, the unadsorbed virus was removed, and the monolayer was washed with phosphate-buffered saline. Finally, culture medium containing different concentrations of the compound was added. Controls without drug were grown in parallel. The cells were then incubated at 37°C. When the control cultures without drug were completely destroyed, total virus yield was determined by plaque formation in Vero cells. Cultures with drug were removed with a rubber policeman (sets of four wells per each compound concentration) and sonicated, and the sonicate was centrifuged to remove cellular debris. The virus titer was expressed in PFU and counted on the days 7 or 8 after infection.
Effect 
RESULTS
Actinobolin and tetracenomycin C were devoid of activity against ASF virus, whereas megalomycin C, suramin, atropine, and carrageenan were rather effective (Fig. 1) . Thus, 10 ,ug of carrageenan per ml fully protected the cell monolayer from destruction by ASF virus, with signs of no cytotoxicity at concentrations up to 200 ,ug/ml. Megalomycin C was also quite effective in preventing virus replication; however, cytotoxicity was observed at a concentration of 50 ,ug/ml. Atropine and suramine also protected Vero cells against ASF virus.
The activity of these four compounds against ASFV replication was measured by formation of infectious virus particles. In so doing, Vero cell monolayers were infected at 0.5 PFU per cell, and after absorption, different concentrations of each compound were added. The virus was collected after 72 h of incubation and titrated. Figure 2 shows that 10 ,ug of megalomycin C per ml inhibited virus growth by 1 log, 20 ,ug/ml inhibited virus growth by 2 logs. Suramin inhibited virus growth by 2 logs at 100 ,ug/ml and by 2.5 logs at 250 ,ug/ml. Atropine inhibited virus growth by 1.5 logs at 100 p.g/ml and by 2.5 logs at 200 ,ug/ml. Finally, carrageenan inhibited virus growth by 1.3 logs at 100 ,ug/ml and by 1.8 logs at 200 ,ug/ml.
The time course of formation of infectious particles was also examined (Fig. 3) . The inhibition of virus growth by megalomycin C, atropine, and carrageenan was constant with respect to growth in control cultures throughout the To analyze in more detail the possible toxic effects of these compounds on cell growth, cells were seeded at low density and counted 3 days later. The dose of drug that reduced cell growth by 50% is shown in Table 1 .
The direct virus-inactivating effect of the different compounds was also examined. No virucidal activity was observed against ASF virus with any of the compounds tested.
To calculate the therapeutic index of these compounds against ASF virus, we determined the median inhibitory dose divided by the drug concentration that reduced by 50% virus production assayed by plaque formation, (Table 1) . According to these data, the antiviral index is 18 for suramin, 12.5 for megalomycin C, 2.8 for atropine, and 5 for carrageenan. On the other hand, the most active compound was megalomycin C with a median effective dose of 4 ,ug/ml. DISCUSSION We have explored the activity of broad-spectrum antiviral agents against ASF virus (1) . In the present study megalomycin C and suramin were shown to have promising activity against ASF virus, with megalomycin C displaying the lowest MIC (4 ,uglml) and with suramin showing the lowest toxicity for cultured cells. Both compounds compared well with 5-iodo-2'-deoxyuridine or phosphonoacetic acid, which have been reported to be inhibitors of ASF virus (8, 9, 14) . Studies in whole animals are necessary, however, to verify the potential of any of these agents against this disease.
The results of this study provide new selective inhibitors of ASF virus. The elucidation of the mode of action of these agents could contribute to studies of the molecular biology of ASF virus. It is already known that suramin blocks the reverse transcriptase of retroviruses by competing with the primer (4). More recently suramin was reported to be active 
